Evy Lundgren-Åkerlund

67 year

Health Technology

Profile

Dr. Evy Lundgren-Åkerlund is a CEO, Head-Business & Administration at Xintela AB.
She is on the Board of Directors at Targinta AB.
Dr. Lundgren-Åkerlund was previously employed as a Chief Executive Officer & Head-Operations by Lund Life Science Incubator and a Vice President-Research & Development by Cartela AB.

Evy Lundgren-Åkerlund active positions

Companies	Position	Start
XINTELA AB	Founder	2008-12-31
Targinta AB Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The private company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022.	Director/Board Member	-

All active positions of Evy Lundgren-Åkerlund

Former positions of Evy Lundgren-Åkerlund

Companies	Position	End
Lund Life Science Incubator	Chief Executive Officer	2011-12-31
Cartela AB Cartela AB Pharmaceuticals: MajorHealth Technology Cartela AB develops therapies for arthritic diseases. It products are mainly used by osteoarthritis and rheumatoid arthritis. Its business is based on the cell surface molecules, integrants a10ß1 and a11ß1. The company was founded by Evy Lundgren-Åkerlund and Donald Gullberg in 2000 and is headquartered in Lund, Sweden.	Founder	2008-12-23

See the detail of Evy Lundgren-Åkerlund's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Evy Lundgren-Åkerlund's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
XINTELA AB	Health Technology

Private companies	3
Cartela AB Cartela AB Pharmaceuticals: MajorHealth Technology Cartela AB develops therapies for arthritic diseases. It products are mainly used by osteoarthritis and rheumatoid arthritis. Its business is based on the cell surface molecules, integrants a10ß1 and a11ß1. The company was founded by Evy Lundgren-Åkerlund and Donald Gullberg in 2000 and is headquartered in Lund, Sweden.	Health Technology
Lund Life Science Incubator
Targinta AB Targinta AB BiotechnologyHealth Technology Part of Xintela AB, Targinta AB develops targeting and toxin-armed antibodies for cancer. The private company is based in Lund, Sweden. Peter Ekolind has been the CEO of the Swedish company since 2022.	Health Technology

See company connections